Lexaria Bioscience (LEXX) said Wednesday it received the independent ethics board approval to initiate a human pilot study to compare an oral version of liraglutide with the conventional injected method.
The company said the oral version is formulated using DehydraTECH-processing and the pilot study will focus on safety and pharmacokinetic performance in humans.
Novo Nordisk markets liraglutide's injectable form as Saxenda and Victoza for weight loss and treatment of diabetes.
Shares of Lexaria were up over 6% in recent trading.
Price: 2.06, Change: +0.13, Percent Change: +6.94
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.